1. Schoetensack, W., Bruckschen, E.G., and Zech, K. (1983) ‘Urapidil’, in A. Scriabine (ed.), New Drugs Annual: Cardiovascular Drugs, Raven Press, New York, pp. 19–48.
2. Jackisch, R., Kasakov, L., Feuerstein, T.J., and Hertting, G. (1987) ‘Effects of urapidil on neurotransmitter release in CNS tissuein vitro’Arch. int. Pharmacodyn. Ther. 285, 5–24.
3. Sanders, K.H., Kilian, U., Kolassa, N., and Schoetensack, W. (1985) ‘Influence of urapidil on a-and 13-adrenoceptors in pithed rats’, J. Auton. Pharmac. 5, 307–316.
4. Van Zwieten, P.A., de Jonge, A., Wilffert, B., Timmermans, P.B.M.W.M., Beckeringh, J.J., and Thoolen, M.J.M.C. (1985) ‘Cardiovascular effects and interaction with adrenoceptors of urapidil’, Arch. int. Pharmacodyn. Ther. 276, 180–201.
5. Ramage, A.G. (1986) ‘A comparison of the effects of doxazosin and alfuzosin with those of urapidil on preganglionic sympathetic nerve activity in anesthetized cats’, Eur. J. Pharmacol. 129, 307–314.